Posts Archive

NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

NCT03631043: Phase 1 - Personalized Vaccine in Treating Participants With Smoldering MM

NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM

NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM

NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM - MMY3019 CEPHEUS

NCT03665155: Phase 1/2 - PET Imaging MM with 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Ab

NCT03549442: Phase 1 - CART-BCMA +/- huCART19 as Consolidation High Risk MM

NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)

NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma

NCT03489525: Phase 1: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228)

NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)

NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)

NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)

NCT03777410: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)

NCT03657251: MMRF CureCloud Research Initiative

IMF - International Myeloma Foundation: Understanding Clinical Trials

NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17